6
H index
3
i10 index
118
Citations
Paolo Pertile : Citation Profile
Università degli Studi di Verona | RESEARCH PRODUCTION: 21 Articles 19 Papers RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
17 years (2006 - 2023). Relations with other researchers
Works with:
Authors registered in RePEc who have co-authored more than one work in the last five years with Paolo Pertile. | Is cited by:
| Cites to:
|
Main data
Where Paolo Pertile has published?
| Journals with more than one article published | # docs |
|---|---|
| Health Economics | 5 |
| Journal of Health Economics | 3 |
| Journal of Public Economic Theory | 2 |
| Applied Health Economics and Health Policy | 2 |
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Working Papers / University of Verona, Department of Economics | 11 |
| Working Papers / Fondazione Eni Enrico Mattei | 2 |
Recent works citing Paolo Pertile (2025 and 2024)
| Year | Title of citing document |
|---|---|
| 2024 | Raising America’s future: Search for optimal child-related transfers. (2024). Komada, Oliwia. In: Economic Modelling. RePEc:eee:ecmode:v:138:y:2024:i:c:s0264999324001214. Full description at Econpapers || Download paper |
| 2024 | With a little help from my (neighbouring) friends. ‘Border region patient mobility’ in the European Union: A policy analysis. (2024). LEVAGGI, ROSELLA ; Frischhut, Markus. In: Health Policy. RePEc:eee:hepoli:v:146:y:2024:i:c:s0168851024001246. Full description at Econpapers || Download paper |
| 2025 | Price regulation and competition among on-patent anticancer drugs in Italy. (2025). Mancusi, Maria ; Vassallo, Chiara ; Fiorentino, Francesca ; di Costanzo, Alessandra ; Candelora, Laura ; Caimmi, Michele ; Canali, Beatrice. In: Health Policy. RePEc:eee:hepoli:v:157:y:2025:i:c:s0168851025001046. Full description at Econpapers || Download paper |
| 2024 | Competition, value-based prices and incentives to research personalised drugs. (2024). LEVAGGI, ROSELLA. In: Socio-Economic Planning Sciences. RePEc:eee:soceps:v:93:y:2024:i:c:s0038012124000697. Full description at Econpapers || Download paper |
| 2024 | The role of the quality infrastructure within socio-technical transformations: A European perspective. (2024). Blind, Knut. In: Technological Forecasting and Social Change. RePEc:eee:tefoso:v:199:y:2024:i:c:s0040162523007047. Full description at Econpapers || Download paper |
| 2024 | Favorable tax treatment of older workers in general equilibrium. (2024). Gustafsson, Johan. In: Umeå Economic Studies. RePEc:hhs:umnees:1023. Full description at Econpapers || Download paper |
| 2024 | Spatial Competition Models in Health Care Markets: A Review. (2024). LEVAGGI, ROSELLA. In: Review of Industrial Organization. RePEc:kap:revind:v:65:y:2024:i:3:d:10.1007_s11151-024-09978-6. Full description at Econpapers || Download paper |
| 2025 | Competition matters: uniform vs. indication-based pricing of pharmaceuticals. (2025). Straume, Odd Rune ; Brekke, Kurt ; Dalen, Dag Morten. In: NIPE Working Papers. RePEc:nip:nipewp:1/2025. Full description at Econpapers || Download paper |
| 2025 | Pension reforms, longer working horizons, and absence from work. (2025). Rocco, Lorenzo ; brunello, giorgio ; Paola, Maria. In: Journal of Population Economics. RePEc:spr:jopoec:v:38:y:2025:i:1:d:10.1007_s00148-025-01074-7. Full description at Econpapers || Download paper |
| 2025 | Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability. (2025). Goettsch, Wim G ; Mantel-Teeuwisse, Aukje K ; Leopold, Christine ; Vreman, Rick A. In: PharmacoEconomics. RePEc:spr:pharme:v:43:y:2025:i:1:d:10.1007_s40273-024-01433-4. Full description at Econpapers || Download paper |
| 2025 | Pharmaceutical Regulation and Incentives for Innovation in an International Perspective. (2025). Dubois, Pierre. In: TSE Working Papers. RePEc:tse:wpaper:131002. Full description at Econpapers || Download paper |
| 2024 | An analysis of a rural hospitals investment decision under different payment systems. (2024). Guo, Xidong. In: Health Economics. RePEc:wly:hlthec:v:33:y:2024:i:4:p:714-747. Full description at Econpapers || Download paper |
Works by Paolo Pertile:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2023 | Dynamic, incentive-compatible contracting for health services In: FEEM Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2023 | Dynamic, incentive-compatible contracting for health services.(2023) In: Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
| 2014 | Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies In: Journal of the Royal Statistical Society Series A. [Full Text][Citation analysis] | article | 8 |
| 2017 | A Bayesian decision theoretic model of sequential experimentation with delayed response In: Journal of the Royal Statistical Society Series B. [Full Text][Citation analysis] | article | 10 |
| 2015 | A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response.(2015) In: Discussion Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 10 | paper | |
| 2008 | Investment in Health Technologies in a Competitive Model with Real Options In: Journal of Public Economic Theory. [Full Text][Citation analysis] | article | 4 |
| 2017 | The Dynamics of Pharmaceutical Regulation and R&D Investments In: Journal of Public Economic Theory. [Full Text][Citation analysis] | article | 5 |
| 2013 | The dynamics of pharmaceutical regulation and R&D investments.(2013) In: Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 5 | paper | |
| 2014 | Two-part payments for the reimbursement of investments in health technologies In: Health Policy. [Full Text][Citation analysis] | article | 9 |
| 2012 | Static and dynamic efficiency of irreversible health care investments under alternative payment rules In: Journal of Health Economics. [Full Text][Citation analysis] | article | 14 |
| 2010 | Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules.(2010) In: Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 14 | paper | |
| 2016 | Late-stage pharmaceutical R&D and pricing policies under two-stage regulation In: Journal of Health Economics. [Full Text][Citation analysis] | article | 7 |
| 2015 | Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation.(2015) In: Discussion Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 7 | paper | |
| 2021 | R&D and market size: Who benefits from orphan drug legislation? In: Journal of Health Economics. [Full Text][Citation analysis] | article | 4 |
| 2017 | A large scale OLG model for the analysis of the redistributive effects of policy reforms In: European Journal of Political Economy. [Full Text][Citation analysis] | article | 19 |
| 2006 | Technology adoption, quality and health care costs: a review of the literature In: STUDI ECONOMICI. [Full Text][Citation analysis] | article | 1 |
| 2009 | The timing of adoption of positron emission tomography: a real options approach In: Health Care Management Science. [Full Text][Citation analysis] | article | 1 |
| 2009 | An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography In: International Journal of Health Economics and Management. [Full Text][Citation analysis] | article | 2 |
| 2015 | The fiscal disadvantage of young Italians: a new view on consolidation and fairness In: The Journal of Economic Inequality. [Full Text][Citation analysis] | article | 1 |
| 2020 | Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 6 |
| 2020 | Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition” In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2016 | Redistribution at the local level: the case of public childcare in Italy In: International Review of Economics. [Full Text][Citation analysis] | article | 4 |
| 2013 | Redistribution at the Local Level: The Case of Public Childcare in Italy.(2013) In: Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 4 | paper | |
| 2011 | Dynamic, economic approaches to HTA under uncertainty In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2012 | Public finance consolidation and fairness across living generations: the case of Italy In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2014 | L’ISEE in Italia: Una Nota Metodologica Partendo dai Dati IT-SILC In: Working Papers. [Full Text][Citation analysis] | paper | 3 |
| 2019 | R&D and market size: who benefits from orphan drug regulation? In: Working Papers. [Full Text][Citation analysis] | paper | 1 |
| 2016 | Pricing policies when patients are heterogeneous: a welfare analysis In: Working Papers. [Full Text][Citation analysis] | paper | 1 |
| 2015 | Who should monitor job sick leave? In: Working Papers. [Full Text][Citation analysis] | paper | 1 |
| 2012 | Modelling life-course decisions for the analysis of interpersonal and intrapersonal redistribution In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2015 | Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden In: Working Papers. [Full Text][Citation analysis] | paper | 1 |
| 2012 | DRGs: the link between investment in technologies and appropriateness In: Working Papers. [Full Text][Citation analysis] | paper | 1 |
| 2013 | Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective In: Health Economics. [Full Text][Citation analysis] | article | 4 |
| 2019 | Job sick leave: Detecting opportunistic behavior In: Health Economics. [Full Text][Citation analysis] | article | 0 |
| 2020 | Which valued‐based price when patients are heterogeneous? In: Health Economics. [Full Text][Citation analysis] | article | 4 |
| 2020 | The impact of managed entry agreements on pharmaceutical prices In: Health Economics. [Full Text][Citation analysis] | article | 4 |
| 2021 | A reply to “Who would benefit from average value‐based pricing?” In: Health Economics. [Full Text][Citation analysis] | article | 0 |
| 2022 | Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany In: Health, Econometrics and Data Group (HEDG) Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2010 | Optimal sequential sampling rules for the economic evaluation of health technologies In: Discussion Papers. [Full Text][Citation analysis] | paper | 2 |
| 2018 | Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence In: Discussion Papers. [Full Text][Citation analysis] | paper | 1 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated December, 22 2025. Contact: CitEc Team